GE HealthCare (Nasdaq: GEHC) announces a groundbreaking advancement in cardiac care with the launch of Caption AI artificial intelligence (AI)-driven software on the Vscan Air SL handheld ultrasound system. This innovative technology aims to empower more clinicians to perform rapid cardiac assessments at the point of care, ultimately enhancing patient outcomes.

Expanding Access to Cardiac Care: Caption AI on Vscan Air SL enables medical professionals to capture diagnostic-quality images with real-time guidance, streamlining the process and boosting confidence in image acquisition. This advancement is particularly significant in resource-constrained settings, where rapid echocardiographic assessments are essential yet challenging.

Empowering Clinicians with AI Guidance: Cardiologist Jordan B. Strom, M.D., MSc., emphasizes the transformative potential of AI-guided ultrasound technology in cardiac care. Caption AI provides users, both experts and newcomers to ultrasound, with step-by-step visual guidance, ensuring optimal probe movements and image quality. The AutoEF feature further enhances efficiency by automatically calculating left ventricular ejection fraction (LVEF), a critical parameter in cardiac assessment.

A New Era in Cardiac Screening: The integration of Caption AI with Vscan Air SL marks a significant milestone in cardiac screening, empowering users with the tools and guidance necessary for high-quality ultrasound scans. Roland Rott, president and CEO of Ultrasound at GE HealthCare, highlights the strategic significance of this technology integration, solidifying the company's leadership in ultrasound and artificial intelligence.

Advancing Precision Care: The launch of Vscan Air SL with Caption AI underscores GE HealthCare's commitment to precision care and innovation in ultrasound technology. With approximately 60 AI-enabled medical device authorizations in the United States, GE HealthCare leads the industry in AI-enabled ultrasound innovations, furthering its mission to improve patient care across the cardiology care pathway.

Debuting at ACC 2024: GE HealthCare will showcase its suite of innovative products and solutions, including CardioVisio for Atrial Fibrillation, at the 2024 American College of Cardiology Annual Scientific Session & Expo in Atlanta. This comprehensive portfolio reflects GE HealthCare's dedication to delivering excellence across the continuum of cardiovascular care, from diagnosis to post-treatment monitoring.

This pioneering advancement in cardiac ultrasound technology promises to revolutionize cardiac care, empowering clinicians to make timely and accurate decisions, ultimately improving patient outcomes and advancing the fight against cardiovascular disease.